Takeda launches Adzynma

Adzynma is the first recombinant ADAMTS13 enzyme replacement therapy for treating Congenital Thrombotic Thrombocytopenic Purpura.

Related Keywords

Spero Cataland ,Julie Kim ,Us Thrombotic Microangiopathy Alliance ,Wexner Medical Center ,Ohio State University ,Drug Administration ,Microangiopathy Alliance ,